JCC: 生物制剂和免疫调节剂联合疗法优于单一疗法,可减少与炎症性肠病相关并发症的风险

2020-10-09 MedSci原创 MedSci原创

英夫利昔单抗和硫唑嘌呤的联合治疗比单用一种药物治疗克罗恩病[CD]和溃疡性结肠炎[UC]更为有效。

         英夫利昔单抗和硫唑嘌呤的联合治疗比单用一种药物治疗克罗恩病[CD]和溃疡性结肠炎[UC]更为有效。但是,尚不确定这些好处是否在现实世界的临床实践以及生物制剂和免疫调节剂的其他组合一样适用。所以,本项研究旨在对此进行相关研究。

 

         研究人员收集了来自加拿大四个省的医疗数据,这些省份总共纳入了78413例炎症性肠病[IBD]患者,其中11244名接受抗肿瘤坏死因子[anti-TNF]药物治疗。主要的观察结局是首次出现治疗失败:计划外的IBD相关住院,IBD相关手术,新/复发性皮质类固醇使用或抗TNF转换事件的出现。多变量Cox比例风险建模用于评估目标结果与接受联合治疗与抗TNF单药治疗之间的关联。使用多变量回归模型评估选择免疫调节剂或生物制剂对达到复合结果的影响。

 

        与抗TNF单药治疗相比,联合治疗与CD和UC的治疗无效性显着降低有关(CD:风险比经调整[aHR] 0.77,95%置信区间[CI] 0.66-0.90; UC:aHR 0.72 ,95%CI 0.62-0.84)。联合疗法对CD中的阿达木单抗和英夫利昔单抗同样有效。在UC中,硫唑嘌呤作为免疫调节剂优于甲氨蝶呤(aHR = 1.52 [95%CI 1.02–2.28]),CD中不存在这样的关系(aHR = 1.22 [95%CI 0.96-1.54])。

 

 

         在对现实世界IBD患者数据库的分析中,研究人员发现生物制剂和免疫调节剂联合治疗降低了CD和UC患者治疗失败的可能性。

 

 

原始出处:

Laura E Targownik. Et al. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. Journal of Crohn's and Colitis.2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1800325, encodeId=20521800325fe, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jul 19 16:23:37 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646993, encodeId=d1671646993a0, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Sat Oct 17 02:23:37 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826017, encodeId=30d3182601e3e, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Nov 16 07:23:37 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758289, encodeId=00ad1e582893a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Oct 11 13:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709081, encodeId=f1ec1e09081e8, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Fri Jun 04 18:23:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547384, encodeId=8904154e384fe, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Oct 11 03:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1800325, encodeId=20521800325fe, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jul 19 16:23:37 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646993, encodeId=d1671646993a0, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Sat Oct 17 02:23:37 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826017, encodeId=30d3182601e3e, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Nov 16 07:23:37 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758289, encodeId=00ad1e582893a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Oct 11 13:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709081, encodeId=f1ec1e09081e8, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Fri Jun 04 18:23:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547384, encodeId=8904154e384fe, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Oct 11 03:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1800325, encodeId=20521800325fe, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jul 19 16:23:37 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646993, encodeId=d1671646993a0, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Sat Oct 17 02:23:37 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826017, encodeId=30d3182601e3e, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Nov 16 07:23:37 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758289, encodeId=00ad1e582893a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Oct 11 13:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709081, encodeId=f1ec1e09081e8, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Fri Jun 04 18:23:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547384, encodeId=8904154e384fe, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Oct 11 03:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1800325, encodeId=20521800325fe, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jul 19 16:23:37 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646993, encodeId=d1671646993a0, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Sat Oct 17 02:23:37 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826017, encodeId=30d3182601e3e, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Nov 16 07:23:37 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758289, encodeId=00ad1e582893a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Oct 11 13:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709081, encodeId=f1ec1e09081e8, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Fri Jun 04 18:23:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547384, encodeId=8904154e384fe, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Oct 11 03:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
    2020-10-11 丁鹏鹏
  5. [GetPortalCommentsPageByObjectIdResponse(id=1800325, encodeId=20521800325fe, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jul 19 16:23:37 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646993, encodeId=d1671646993a0, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Sat Oct 17 02:23:37 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826017, encodeId=30d3182601e3e, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Nov 16 07:23:37 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758289, encodeId=00ad1e582893a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Oct 11 13:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709081, encodeId=f1ec1e09081e8, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Fri Jun 04 18:23:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547384, encodeId=8904154e384fe, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Oct 11 03:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1800325, encodeId=20521800325fe, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jul 19 16:23:37 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646993, encodeId=d1671646993a0, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Sat Oct 17 02:23:37 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826017, encodeId=30d3182601e3e, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Nov 16 07:23:37 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758289, encodeId=00ad1e582893a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Oct 11 13:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709081, encodeId=f1ec1e09081e8, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Fri Jun 04 18:23:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547384, encodeId=8904154e384fe, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Oct 11 03:23:37 CST 2020, time=2020-10-11, status=1, ipAttribution=)]

相关资讯

IBD:血清miRNA是与小儿炎症性肠病的治疗反应相关的生物标志物

炎症性肠病(IBD)可以连续和同时接受多种治疗。治疗方法是根据疾病表型分层选择的。

TAG:铁剂在接受抗肿瘤坏死因子-α药物治疗的炎症性肠病患者中的作用

炎性肠病(IBD)是一种慢性炎性疾病,其主要形式为溃疡性结肠炎(UC)和克罗恩病(CD)。IBD的主要症状和体征在肠道。但是,肠外表现很常见。

AP&T: 炎症性肠病患者使用抗肿瘤坏死因子药物以及硫唑嘌呤治疗对淋巴瘤发生风险的影响

炎性肠病(IBD)是胃肠道的慢性炎性疾病,影响全球约1000万患者。硫唑嘌呤和肿瘤坏死因子拮抗剂(抗TNF)的疗效已得到公认。

AP&T: 影响维多珠单抗和乌斯他单抗治疗的炎性肠病患者安全性的因素只有合并症而不是患者年龄

炎症性肠病(IBD)包括克罗恩氏病(CD)和溃疡性结肠炎(UC),是一种慢性免疫介导的疾病,主要影响胃肠道,其特征是疾病的复发和缓解反复交替。

Dig Dis Sci:贫血严重程度与炎性肠病的医疗保健利用率和费用增加相关

克罗恩氏病(CD),溃疡性结肠炎(UC)和未分类IBD(IBDU)是构成炎症性肠病(IBD)的一组以肠道炎症为特征的慢性疾病,经常会出现肠外表现。

IBD:炎症性肠病患者唾液和血清的炎症特征不一致

炎症性肠病(IBD),包括克罗恩病(CD)和溃疡性结肠炎(UC)。它是一组慢性免疫介导的炎症性疾病,影响了全球超过350万人。患者不光可以再肠道